$19.8 Bn Osteoporosis Drugs Market Opportunities And Strategies To 2034, Fueled By Aging Population And Rising Healthcare Spend, Though High Costs Pose A Challenge

(MENAFN- GlobeNewsWire - Nasdaq) Growth in the historic period resulted from the health insurance expansion, increase in bone fractures and comorbidities and government and health initiatives. Factors that negatively affected growth in the historic period were safety concerns. Going forward, increasing aging population, rising healthcare expenditure, economic growth in emerging markets and rising prevalence of osteoporosis will drive the growth. Factor that could hinder the growth of the osteoporosis market in the future include high costs.

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Osteoporosis Drugs Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering.
This report describes and explains the osteoporosis drugs market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global osteoporosis drugs market reached a value of nearly $12.88 billion in 2024, having grown at a compound annual growth rate (CAGR) of 2.42% since 2019. The market is expected to grow from $12.88 billion in 2024 to $15.69 billion in 2029 at a rate of 4.02%. The market is then expected to grow at a CAGR of 4.77% from 2029 and reach $19.8 billion in 2034.
The global osteoporosis drugs market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 39.7% of the total market in 2023. Amgen Inc. was the largest competitor with a 9.33% share of the market, followed by Eli Lilly and Company with 4.29%, Pfizer Inc. 3.76%, Eisai Co., Ltd. with 3.73%, Apotex Inc. with 3.65%, AbbVie Inc. with 3.33%, Novartis AG with 3.32%, Sanofi S.A. with 3.01%, GSK plc with 2.78% and Daiichi Sankyo Company, Limited with 2.52%.

North America was the largest region in the osteoporosis drugs market, accounting for 43.50% or $5.6 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the osteoporosis drugs market will be Asia Pacific and South America where growth will be at CAGRs of 5.73% and 4.44% respectively. These will be followed by Eastern Europe and Western Europe where the markets are expected to grow at CAGRs of 4.25% and 3.58% respectively.
The osteoporosis drugs market is segmented by type into bisphosphonates, selective estrogen receptor modulators (SERMs), RANK ligand inhibitors, parathyroid hormone therapy, calcitonin, sclerostin inhibitor and other drug class. The bisphosphonates market was the largest segment of the osteoporosis drugs market segmented by type, accounting for 34.45% or $4.43 billion of the total in 2024. Going forward, the RANK ligand inhibitors segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by type, at a CAGR of 4.76% during 2024-2029.
The osteoporosis drugs market is segmented by administration into oral and injectable. The oral market was the largest segment of the osteoporosis drugs market segmented by administration, accounting for 57.71% or $7.43 billion of the total in 2024. Going forward, the injectable segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by administration, at a CAGR of 4.71% during 2024-2029.
The osteoporosis drugs market is segmented by distribution channel into retail pharmacies, hospital pharmacies and online sales. The hospital pharmacies market was the largest segment of the osteoporosis drugs market segmented by distribution channel, accounting for 42.89% or $5.52 billion of the total in 2024. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by distribution channel, at a CAGR of 4.50% during 2024-2029.
The osteoporosis drugs market is segmented by application into primary osteoporosis and secondary osteoporosis. The primary osteoporosis market was the largest segment of the osteoporosis drugs market segmented by application, accounting for 78.19% or $10.07 billion of the total in 2024. Going forward, the primary osteoporosis segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by application, at a CAGR of 4.11% during 2024-2029.
The top opportunities in the osteoporosis drugs markets segmented by type will arise in the bisphosphonates segment, which will gain $1.07 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs market segmented by administration will arise in the oral segment, which will gain $1.39 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs markets segmented by distribution channel will arise in the retail pharmacies segment, which will gain $1.12 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs markets segmented by application will arise in the primary osteoporosis segment, which will gain $2.24 billion of global annual sales by 2029. The osteoporosis drugs market size will gain the most in USA at $870.53 million.
Market-trend-based strategies for the osteoporosis drugs market include focus on developing innovative solutions, such as teriparatide Injection for the treatment of treatment osteoporosis, development of innovative solutions, such as obtaining regulatory approvals and advancing innovative treatment solutions, such as edirol tablet for osteoporosis treatment.
Player-adopted strategies in the osteoporosis drugs market include focus on expanding business capabilities through the launch of new products. To take advantage of the opportunities, the analyst recommends the osteoporosis drugs companies to focus on developing innovative and accessible treatment solutions, focus on regulatory approvals and innovative treatments, focus on enhancing medication adherence and targeted therapeutic options, focus on RANK ligand inhibitors for business growth, focus on the injectable segment for growth, expand in emerging markets, focus on expanding distribution channels for osteoporosis drugs, focus on developing competitive and flexible pricing strategies for osteoporosis drugs, focus on targeted marketing and educational campaigns for osteoporosis drugs, focus on physician engagement and influencer collaborations for osteoporosis drugs, focus on online sales for growth in osteoporosis drugs market and focus on primary osteoporosis market segment.

Key Attributes:

Report Attribute	Details
No. of Pages	317
Forecast Period	2024 - 2034
Estimated Market Value (USD) in 2024	$12.88 Billion
Forecasted Market Value (USD) by 2034	$19.8 Billion
Compound Annual Growth Rate	4.4%
Regions Covered	Global

Major Market Trends

• Innovative Osteoporosis Treatment Launched To Enhance Patient Outcomes
• Innovative Approaches and Regulatory Approvals Driving Treatment Advancements
• Advance Treatment With Targeted Therapeutic Option For Better Osteoporosis Treatment

Key Mergers and Acquisitions

• Bone Health Technologies Acquired Wellen
• Nestle Health Science Acquired Bountiful Company

Companies Featured

• Donaldson Company Inc.
• Freudenberg Filtration Technologies SE & Co. KG
• Parker Hannifin Corp.
• Entegris Inc.
• American Air Filter Company Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi S.A.
• GSK plc
• Daiichi Sankyo Company, Limited
• Takeda Pharmaceutical Company
• Teva Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• Merck Sharp & Dohme
• Roche Holding AG
• Transcenta Holding Ltd.
• Shanghai Henlius Biotech
• Enzene Biosciences Ltd.
• Eden Biologics
• Zydus Lifesciences
• Mabwell (Shanghai) Bioscience Co., Ltd.
• Strides Pharma Science
• Asahi Kasei Corporation
• Pharmac
• Axial Therapeutics
• Acrux Limited
• Cynata Therapeutics
• Kyowa Kirin
• Cadila Pharmaceuticals
• Luye Pharma Group
• Pharmed Limited
• Chugai Pharmaceutical Co. Ltd.
• Towa Pharmaceutical Co., Ltd.
• GlaxoSmithKline plc
• UCB S.A.
• Sandoz AG
• Enzene Biosciences Limited
• Fresenius Kabi
• Gedeon Richter
• Alvotech
• Mabxience Holding, S.L.
• Theramex
• Novo Nordisk A/S
• Bristol Myers Squibb
• Ferring Pharmaceuticals
• Laboratoires Servier
• Grunenthal GmbH
• OsteoSys
• Medimaps Group SA
• Pharmanovia
• Glenmark Pharmaceuticals
• Dr. Max Group
• Polpharma
• Celon Pharma
• Hasco-Lek
• Biofarma S.A.
• Sandoz
• Mylan Pharmaceuticals
• Radius Health, Inc.
• Horizon Therapeutics
• Levolta Pharmaceuticals, Inc.
• Tabuk Pharmaceuticals
• EVA Pharma
• AstraZeneca
• Abbott Laboratories
• Adcock Ingram
• Aspen Pharmacare Holdings Limited
• IBN SINA Pharmaceutical
• Solal Technologies

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Osteoporosis Drugs Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN09052025004107003653ID1109528350